LitAlert ~~ GeneLit.com

    • Pathogenic Variant Spectrum in Breast Cancer Risk Genes in Finnish Patients.
    • Nurmi AK, Suvanto M, Dennis J, Aittomäki K, Blomqvist C, Nevanlinna H.
    • Cancers (Basel). 2022 Dec 14;14(24):6158. doi: 10.3390/cancers14246158.

    • Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients.
    • Gurioli G, Tedaldi G, Farolfi A, Petracci E, Casanova C, Comerci G, Danesi R, Arcangeli V, Ravegnani M, Calistri D, Zampiga V, Cangini I, Fonzi E, Virga A, Tassinari D, Rosati M, Ulivi P, De Giorgi U.
    • Int J Mol Sci. 2022 Dec 13;23(24):15789. doi: 10.3390/ijms232415789.

    • Real World Cost-Effectiveness Analysis of Population Screening for BRCA Variants among Ashkenazi Jews Compared with Family History-Based Strategies.
    • Michaelson-Cohen R, Cohen MJ, Cohen C, Greenberg D, Shmueli A, Lieberman S, Tomer A, Levy-Lahad E, Lahad A.
    • Cancers (Basel). 2022 Dec 12;14(24):6113. doi: 10.3390/cancers14246113.

    • Molecular profiling of male breast cancer by multigene panel testing: implications for precision oncology.
    • Valentini V, Silvestri V, Bucalo A, Conti G, Karimi M, Di Francesco L, Pomati G, Mezi S, Cerbelli B, Pignataro MG, Nicolussi A, Coppa A, D'Amati G, Giannini G, Ottini L.
    • Front Oncol. 2022 Dec 12;12:1092201. doi: 10.3389/fonc.2022.1092201.

    • Myriad Genetics Generates More Data on its PRS's Ability to Identify Who Will Develop Breast Cancer.
    • Ray F.
    • Precision Oncology News. 2022 Dec 12.

    • Evaluation of out-of-pocket pay genetic testing in a publicly funded healthcare system.
    • Grant P, Cook CB, Langlois S, Nuk J, Mung S, Zhang Q; GenCOUNSEL Study, Lynd LD, Austin J, Elliott AM.
    • Clin Genet. 2022 Dec 11. doi: 10.1111/cge.14276. Epub ahead of print.

    • Cancer Moonshot 2.0, health equity and BRCA1/2 testing.
    • Sorscher S.
    • J Cancer Policy. 2022 Dec 8:100379. doi: 10.1016/j.jcpo.2022.100379. Epub ahead of print.
    • Letter